Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506
Affiliations
- PMID: 1703354
- PMCID: PMC2967371
Item in Clipboard
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506
Transplant Proc.
1991 Feb.
Abstract
FK 506 therapy with low doses of steroids was adequate to control rejection in most liver recipients. Rejection episodes were readily reversed with single IV doses of methylprednisone or hydrocortisone. Short courses of OKT3 (3 to 5 days 5-10 mL) controlled severe rejections. The rate of retransplantation directly due to rejection was low (1.6%). There was a limited need for steroids either early or out to 6 to 12 months.
Figures
Percentage Survival of patients and primary transplants on FK 506 over the follow-up period (n = 125).
Similar articles
-
Experience with Orthoclone OKT3 monoclonal antibody in liver transplantation.Am J Kidney Dis. 1988 Feb;11(2):141-4. doi: 10.1016/s0272-6386(88)80199-9. Am J Kidney Dis. 1988. PMID: 3124609 Free PMC article. Clinical Trial.
-
Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.Liver Transpl. 2001 Mar;7(3):220-5. doi: 10.1053/jlts.2001.22455. Liver Transpl. 2001. PMID: 11244163
-
Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?Transplant Proc. 1993 Aug;25(4):2693-4. Transplant Proc. 1993. PMID: 7689279 Clinical Trial. No abstract available.
-
Therapy for acute rejection in pediatric organ transplant recipients.Paediatr Drugs. 2003;5(2):81-93. doi: 10.2165/00128072-200305020-00002. Paediatr Drugs. 2003. PMID: 12529161 Review.
-
Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.Drugs. 1996 May;51(5):865-94. doi: 10.2165/00003495-199651050-00010. Drugs. 1996. PMID: 8861551 Review.
Cited by
-
Clinical intestinal transplantation: focus on complications.Transplant Proc. 1992 Jun;24(3):1238-40. Transplant Proc. 1992. PMID: 1604600 Free PMC article. No abstract available.
-
Prediction of Early Recurrence of Solitary Hepatocellular Carcinoma after Orthotopic Liver Transplantation.Sci Rep. 2019 Nov 1;9(1):15855. doi: 10.1038/s41598-019-52427-8. Sci Rep. 2019. PMID: 31676847 Free PMC article. Clinical Trial.
-
Decreased incidence of viral infections in liver transplant recipients. Possible effects of FK506?Dig Dis Sci. 1994 Jan;39(1):15-8. doi: 10.1007/BF02090054. Dig Dis Sci. 1994. PMID: 7506641 Free PMC article.
-
Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy.J Clin Invest. 1996 Jun 1;97(11):2433-9. doi: 10.1172/JCI118690. J Clin Invest. 1996. PMID: 8647935 Free PMC article.
-
One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.Transplant Proc. 1995 Feb;27(1):1099-104. Transplant Proc. 1995. PMID: 7533353 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical